BCL2L1 and breast cancer: In addition to shRNA knockdown of CtBP2 in BON1 PNET cells, we used CRISPR-Cas9 to knock out (KO) CtBP2 in the MDA-MB-231 breast cancer cell line to further test the regulation of nuclear translocation of Bcl-xL by CtBP2.